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Abstract
Fibrates lower triglycerides and raise HDL cholesterol in dyslipidemic patients, but show heterogeneous treatment
response. We used k-means clustering to identify three representative NMR lipoprotein profiles for 775 subjects from the
GOLDN population, and study the response to fenofibrate in corresponding subgroups. The subjects in each subgroup
showed differences in conventional lipid characteristics and in presence/absence of cardiovascular risk factors at baseline;
there were subgroups with a low, medium and high degree of dyslipidemia. Modeling analysis suggests that the difference
between the subgroups with low and medium dyslipidemia is influenced mainly by hepatic uptake dysfunction, while the
difference between subgroups with medium and high dyslipidemia is influenced mainly by extrahepatic lipolysis
disfunction. The medium and high dyslipidemia subgroups showed a positive, yet distinct lipid response to fenofibrate
treatment. When comparing our subgroups to known subgrouping methods, we identified an additional 33% of the
population with favorable lipid response to fenofibrate compared to a standard baseline triglyceride cutoff method.
Compared to a standard HDL cholesterol cutoff method, the addition was 18%. In conclusion, by using constructing
subgroups based on representative lipoprotein profiles, we have identified two subgroups of subjects with positive lipid
response to fenofibrate therapy and with different underlying disturbances in lipoprotein metabolism. The total subgroup
with positive lipid response to fenofibrate is larger than subgroups identified with baseline triglyceride and HDL cholesterol
cutoffs.
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Introduction
Fibrates are prescribed to lower plasma triglycerides and raise
HDL cholesterol (HDLc) in dyslipidemic patients. These drugs are
not universal in efficacy; patients respond heterogeneously, and
the most recent data show that fibrates only reduce cardiovascular
events in specific subgroups [1–3]. It is therefore important to find
improved methods for identifying those patients that will respond
positively to fibrate treatment.
The fact that patients respond heterogeneously to fibrates has
been documented in most of the large clinical trials conducted
with fibrates [4–11]. Subgroups with high triglycerides [8,12], high
HDLc [12], a combination of high triglycerides with low HDLc or
a combination of high triglycerides with a high LDLc/HDLc ratio
[12,13] and diabetic or insulin resistant subjects [14] all proved to
have increased benefit from fibrates in specific studies, when
compared to the general population. Because different studies use
different methods for defining subgroups, apparently it is a
challenge to optimally define the patient subgroup which stands to
see the greatest benefit.
Methods to effectively define this high-benefit subgroup would
be useful for analyzing finished trials and possibly for designing
future clinical trials [15]. In earlier fibrate trials [4–11], owing to
the heterogeneous response to therapy, the benefit of fibrates
could not be shown over the whole population. A method to
effectively identify the responding subgroup would both ensure
that the right patients are treated with fibrates, and that clinical
trials have the largest possible power to detect treatment benefit
by appropriate selection of study participants. In trials that have
already been conducted, correctly identifying the response
subgroup would increase the power of subgroup analysis. For
patients, it would mean a better opportunity to receive efficacious
medication. Effective subgroup identification therefore would
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economics.
Detailed measurements of the plasma lipoprotein profile [16,17]
should provide the basis for improving the patient-subgroup
definition for treatment response to fibrates. Good response to
fibrates has often been associated with an ‘atherogenic lipoprotein
phenotype’ or ‘lipid triad’, which consists of raised triglycerides,
low HDLc and small-sized LDL particles [18]. Fibrates activate
transcription factors called peroxisome proliferator-activated
receptors (PPARs) [19,20]. This results in increased lipolysis of
VLDL particles, increased removal of LDL particles and increased
HDL production [21]. Fibrates, therefore, contribute substantially
to the improvement of the atherogenic lipoprotein phenotype [22].
A detailed plasma lipoprotein profile contains information about
the number of particles in subclasses of HDL, LDL and VLDL,
and thus reflects more aspects of this phenotype than any routine
clinical chemistry measurement. In addition, we have developed
the Particle Profiler model [23,24] to analyze lipoprotein profiles
and detect metabolic disturbances, especially in the VLDL region
through the VLDL performance parameter [25]. Therefore,
lipoprotein profiles contain much information and hold great
potential for improving the definition of fibrate response
subgroups.
From the above we can conclude that it is useful to define the
relationship between baseline lipoprotein profiles and fibrate
treatment response. Therefore, in this study (see Figure 1) we have
used a clustering methodology to delineate subgroups of subjects
with baseline lipoprotein profiles that are representative for the
variation in the population at baseline. We then applied Particle
Profiler to the representative ‘centroid’ lipoprotein profiles to
investigate the metabolic disturbance associated with these
representative profiles. Finally, we investigated whether subgroups
based on the baseline lipoprotein profile clustering segregate the
lipid response to fenofibrate treatment differently than subgroups
based on triglyceride or HDLc cutoffs, as used for previous
subgroup analyses [8,12]. For this purpose, we have used data
from the Genetics of Lipid Lowering Drugs and Diet Network
(GOLDN) study [26], in which fenofibrate was administered to
assess the variable response of triglyceride lowering in a white
population recruited at two genetically homogenous centers with a
very heterogeneous degree of dyslipidemia.
Methods
Study Sample
In the GOLDN study, family members from three-generational
pedigrees were re-recruited from two centers of the ongoing
NHLBI Family Heart Study (Salt Lake City and Minneapolis).
The population can be described as from two genetically
homogeneous centers (predominantly white), and encompassing
a wide distribution in terms of lipid phenotypes. The only lipid
inclusion criterion used was fasting TG ,1500 mg/dL. The
population is highly interrelated; subjects in the present sample
represent 165 different families. The dyslipidemic state of the
subjects is highly heterogeneous.
The subjects underwent a 3-week treatment with a daily dose of
160 mg fenofibrate. Before and after the intervention, lipid
phenotypes were measured using both biochemical measurements
and NMR spectroscopy, after fasting and postprandially after a
dietary fat challenge (as described in [26]). Glucose and insulin
were also measured, and used to calculate the HOMA index for
insulin sensitivity [27]. In the present study, only fasting data are
used. Details regarding the study and protocols followed can be
found in Lai et al. [26]. Written informed consent was obtained
from each participant at his/her screening visit. The GOLDN
protocol and data handling were approved by the Institutional
Review Boards at the University of Minnesota, the University of
Utah, University of Alabama at Birmingham and Tufts University.
Adverse events were monitored, and all incidents were reviewed
by the local Principal Investigator, with any serious adverse events
reported to the Institutional Review Boards at the University of
Minnesota or the University of Utah and the NHLBI. The sample
for this study consists of all 775 participants in GOLDN who had a
complete NMR lipoprotein profile recorded both at baseline and
after fenofibrate intervention.
Subgroup Identification
We applied K-means clustering based on baseline lipoprotein
profile data to identify representative lipoprotein profiles. We
analyzed these lipoprotein profiles using computational modeling
to give insight into representative dyslipidemic states. We also
studied the baseline characteristics and response to fenofibrate of
these subgroups (see Figure 1). By working with baseline lipoprotein
profiles measured in fasting state, we ensure that the subgroups
identified here can be used in clinical practise, if they result useful.
An NMR measurement on a fasting blood sample is more feasible
in clinical practise than on a standardized postprandial sample. So
we use fasting NMR lipoprotein profiles as input to the K-means
clustering routine to ensure that application of our results in the
clinic is feasible.
K-means clustering is an unsupervised classification method
which partitions a dataset into K non-overlapping clusters. First, K
centroids were defined by randomly choosing K different data
points, after which each data point was assigned to the nearest
centroid. We used squared Euclidean distance as distance
measure. Next, the cluster centroids were iteratively updated until
the sum of the distances between the data points and the centroid
in each cluster was minimal. This method was used on the baseline
lipoprotein profile of all subjects to identify subgroups in the
population. This profile was measured by NMR spectroscopy as
described [16,28,29], and particle concentrations from three
VLDL (large, medium and small), four LDL (IDL, large, medium
small and very small) and three HDL (large, medium and small)
subclasses were used, thus providing a 10-dimensional data space
for clustering. To ensure that the classes were in the same range,
the data were normalized: the values were divided by the total
standard deviation in the VLDL, LDL and HDL classes
respectively. To improve reproducibility, clustering was replicated
500 times, and the outcome with lowest total sum of distances was
chosen. The resulting clusters were then sorted on size, such that
the largest cluster was labeled cluster 1. For the used dataset, this
procedure yields a reproducible final result.
We chose K=3 because it led to distinct lipoprotein profiles
that represent the variation in the population. At K=3 both the
LDL and VLDL range major variations in the concentration were
captured, while the means and standard deviations of the clusters
remained fairly separated (see Fig 1). The third added cluster is
therefore an improvement over K=2, since we can identify an
additional representative lipoprotein profile. With K.3, the
means and standard deviations of two of the cluster centroids
became very similar, indicating no real difference in representative
lipoprotein profiles. Moreover, at K=3 baseline characteristics
were clearly different between the three resulting groups. With
K.3 some groups overlapped in important baseline characteris-
tics such as LDL cholesterol concentration. When using the
clustering approach, we do not expect the data to be perfectly
separable into these three clusters. Indeed, other cut-off methods
define a cut-off value that separates the population into two
Two Distinct Fenofibrate Responder Subgroups
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data. In the same way, we do not expect a natural separation in
the population based on the representative lipoprotein profiles.
Still, the clustering is able to identify representative lipoprotein
profiles and define ‘multivariate cut-off groups’ based on these
profiles.
Clustering was performed on baseline NMR profiles of all 775
subjects, men and women together. In this way we were able to
study sex differences to fenofibrate response in subgroups with the
same representative lipoprotein profile. Furthermore, grouping on
TG (low: TG ,150, medium: 150# TG ,200, and high: TG
$200 mg/dL) and on HDLc (low: HDLc ,40 mg/dL for males
and HDLc ,50 mg/dL for females) was implemented. Although
total TG and total LDL and HDLc were measured by NMR as
well, we used the biochemically measured values throughout this
study to facilitate comparison with other studies. Biochemically
and NMR-measured TG are highly correlated (R
2=0.97);
cholesterol measurements were less correlated (the lowest corre-
lation being R
2=0.80 for LDL cholesterol).
Modeling Lipoprotein Profiles
We applied the previously developed Particle Profiler model
[23] to the three representative ‘centroid’ NMR lipoprotein
profiles. Particle Profiler was developed from the idea that
although a single lipoprotein profile does not contain any
lipoprotein metabolic flux information, it is still possible to derive
ratios of metabolic flux parameters if the profile is carefully
analyzed. The model can derive these ‘lipoprotein metabolic
ratios’ by learning from earlier lipoprotein metabolic flux studies
how the metabolic rate constants depend on the size of the
lipoprotein particle [25]. Once the model has incorporated this
knowledge, it can analyze lipoprotein profiles and determine the
‘lipoprotein metabolic ratios’ for each measured profile. In this
Figure 1. Overview of the data analysis approach presented in this paper. Clustering was carried out to identify representative lipoprotein
profiles. The computational model analyzed those representative lipoprotein profiles. In the corresponding subgroups baseline characteristics and
the lipid response to fenofibrate intervention was studied. The results of the subgroup studies were compared to the baseline characteristics and
lipid response to fenofibrate in subgroups identified using triglyceride or HDL cholesterol cut-off methods.
doi:10.1371/journal.pone.0038072.g001
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uptake and production in VLDL, the ratio between lipolysis and
production in VLDL, as well as the average of these last two
ratios, which we have called ‘VLDL performance’ [25].
Since this is the first study in which Particle Profiler was fitted
to NMR lipoprotein profiles, the following calibration steps
needed to be taken. First, each measurement method can
measure particle size slightly differently, the model requires a
correction of the NMR particle size measurement, to compensate
for these differences. This size correction was derived by fitting it
to the three lipoprotein profiles simultaneously, as described in
the File S2, resulting in a size correction dshift = 24.01 nm.
Second, because production fluxes are not known when fitting
an NMR lipoprotein profile, these fluxes were fitted sequentially.
We initially assumed the average production into the VLDL1,
VLDL2, IDL and LDL classes reported by Packard et al [30],
and used those to fit the lipolysis and uptake processes. Then we
fixed lipolysis and uptake and fitted the production fluxes. We
repeated these two steps until we achieved a stable fit of the
lipoprotein particle concentrations. This process cannot produce
accurate values for the lipolysis, uptake and production processes
per se, but can accurately estimate the ratios of these processes,
and the ratios are the information we want to derive. Finally, the
fitting routine uses weights that determine the importance of
deviations in each measured fraction. The weights are given and
explained in the File S2 (numerical values in Supporting Table 4).
Statistical Analysis
After defining subgroups via lipoprotein profile clustering,
triglyceride and HDLc methods, we calculated the baseline
characteristics and the response to fenofibrate intervention in the
subgroups. We compared all continuous variables across sub-
groups by standard Student’s T-tests and reported differences as
significant if p,0.01.
The response is defined as the percent change in biochemically
measured TG, HDLc and LDLc, as well as in NMR measured
LDL size, LDL particle concentration (LDLp) and HDL particle
concentration (HDLp). To detect gender-specific responses, these
numbers were calculated for men and women separately. Because
the percent changes are distributed normally as judged by visual
inspection of the histograms, the differences in response between
groups were also tested for significance by Student’s t-test with
p,0.01.
To compare the outcomes of the different subgrouping
methods, Venn diagrams were drawn to visualize the overlap
between corresponding subgroups. The response in those resulting
groups was calculated and also tested for significant differences by
Student’s t-test with p,0.01.
Results
Clustering Subgroups
The clustering carried out on lipoprotein particle concentra-
tions as measured by NMR spectroscopy, identifies three distinct
lipid-metabolic phenotypes in the population (see Table 1). The
first and largest cluster (45% of subjects) is characterized by low
Table 1. Baseline characteristics of subjects in clustering on lipoprotein profile.
cluster 1 (n=350) cluster 2 (n=297) cluster 3 (n=128)
Age 46617 50615
{ 55614
{{
BMI 26.865.8 29.965.2
{ 30.063.8
{
Female 67% 39% 34%
Total TG (mg/dL) 90643 134655
{ 2906129
{{
Postprandial TG (t=3 hours, mg/dL) 172682 2606105
{ 4776178
{{
Postprandial TG (t=6 hours, mg/dL) 146689 2346120
{ 5136239
{{
Total cholesterol (mg/dL) 180638 189632
{ 223640
{{
LDLc (mg/dL) 114631 129627
{ 137634
{{
HDLc (mg/dL) 54613 4269
{ 3667
{{
LDL size (nm) 21.560.5 20.360.5
{ 19.760.4
{{
LDLp (nmol/L)* 11066301 15516346
{ 19366486
{{
HDLp (nmol/L)* 31653 0 66
{ 2866
{{
HOMA 2.962.1 4.162.8
{ 4.963.1
{
CRP 0.260.4 0.360.3 0.260.2
Glucose (mg/dL) 97616 104616
{ 110626
{{
Drinkers 49% 42% 52%
Smokers 29% 30% 38%
Prior use of lipid-lowering agents 13% 19% 44%
Metabolic syndrome (ATP III) 19% 47% 88%
Diabetes 5% 9% 13%
Hypertension 22% 27% 36%
{indicates significantly different with respect to cluster 1, p,0.01.
{indicates significantly different with respect to cluster 2, p,0.01.
*LDL/HDL particle number (measured by NMR).
doi:10.1371/journal.pone.0038072.t001
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It is also the subgroup with the largest proportion of young
people (68% of subjects below the age of 30 are in cluster 1). The
second and third clusters, in contrast, have an overrepresentation
of obese, high-triglyceridemic, male and insulin-resistant subjects.
The main difference between clusters 2 and 3 lies in the TG
concentration, which is caused by a much higher concentration
of VLDL particles in cluster 3 (Figure 2). All clusters are
separated very clearly by LDL size, which should be expected as
LDL size is a linear combination of the concentrations of the
LDL subclasses on which the clustering was partially based. LDL
particles in cluster 1 are mainly concentrated in the large LDL
subclass (21.2–23 nm), while in clusters 2 and 3 they are mainly
in the very small LDL subclass (18–19.8 nm) [31].
Modeling Results
There was a difference in VLDL performance (see Figure 3a)
between the three lipoprotein profile clusters. As Figure 3b shows,
cluster 1 had a high VLDL performance, cluster 2 had a lower
VLDL performance and cluster 3 had the lowest VLDL
performance. The difference between cluster 1 and 2 in
Figure 3b has a larger changed component along the y-axis,
while the difference between cluster 2 and 3 is mostly due to
changes along the x-axis. As explained by figure 3a, this indicates
that the difference between cluster 1 and 2 is more influenced by
liver uptake dysfunction, while the difference between cluster 2
and 3 is more influenced by extrahepatic lipolysis dysfunction.
Therefore, the three subgroups show differences in underlying
lipoprotein metabolism.
Baseline Comparison with TG and HDLc Subgroups
The baseline characteristics of the subjects in the subgroups
defined by TG and HDLc cutoffs are given in File S2, Supporting
Table 1. The most striking difference between the lipoprotein
profile clustering and the subgrouping is the subgroups’ size, which
is visualized for the HDL subgroups in Figure 4a, and for the TG
subgroups in Figures 4b and 4c. Although for the TG subgroups
many characteristics are roughly comparable (cluster 1 matching
the low, cluster 2 matching the medium and cluster 3 matching the
high TG cutoff subgroup), cluster 2 is about 2.5 times larger than
the medium TG subgroup.
The subgrouping on HDLc leads to two groups that are
essentially independent of sex and age, while the TG subgrouping
and certainly the lipoprotein profile clustering are correlated with
age and gender. TG and HDLc concentrations and LDL size all
differ significantly between all subgroups in all three methods.
LDLc concentration and also HDL particle number is significantly
different between all subgroups in the lipoprotein profile
clustering, but not in the TG subgrouping.
Results of the Fenofibrate Intervention
The results of the fenofibrate intervention, expressed as percent
changes in primary lipid metabolites as well as in some NMR-
specific measures, are summarized in Table 2. The changes are
reported for all three implemented subgrouping methods: cluster-
ing on the NMR measured lipoprotein subclass concentrations
(Table 2), cutoff on total baseline TG concentration (File S2,
Supporting Table 2a), and a sex-dependent cutoff on baseline
HDLc concentration (File S2, Supporting Table 2b).
Clustering subgroups. The three lipoprotein profile-based
clusters each showed a different response to fenofibrate interven-
Figure 2. Mean standardized particle concentrations (unitless) of NMR lipoprotein subclasses in three subgroups based on K-
means clustering. Particle sizes of the various subclasses were the same as described in Freedman, et al. [38].
doi:10.1371/journal.pone.0038072.g002
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(both measured biochemically and by NMR) and for females also
the largest increases in HDLc and particle number. LDL size was
decreased in cluster 1, but by contrast increased in clusters 2 and
3. This was accompanied by a trend towards less LDLc lowering
in these successive clusters. The LDL particle number decreased
most in cluster 2, although among females this decrease was not
significantly larger than in cluster 3. Because fenofibrate is
primarily given to lower triglycerides, increase LDL size, and
increase HDL, we saw the smallest benefit from fenofibrate
treatment on lipid parameters in individuals in cluster 1, while
clusters 2 and 3 showed an increasingly favorable response.
Cluster 2 had the peculiarity of the highest LDL particle response,
significantly so for male subjects. Fenofibrate treatment did not
affect postprandial response differently in different subgroups.
Comparison with HDLc subgroups. Lipoprotein-profile
based clusters identify an additional response subgroup with
respect to the HDLc-based subgroups [12]. The overlap between
the low baseline HDLc subgroup and lipoprotein clusters 2 and 3
taken together comprises 37% of the total population (see
Figure 4a). Also, 12% of the population is included in the low
HDLc subgroup, but not in lipoprotein clusters 2 and 3, while
18% of the population is included in lipoprotein clusters 2 and 3,
and not in the low HDLc subgroup. Table 3 shows that those
subjects included only in lipoprotein clusters 2 and 3 have a
significantly larger LDL particle size increase, and in females also a
larger LDL particle number increase, as a result of fenofibrate
Figure 3. VLDL metabolism status as derived by Particle Profiler from the three representative ‘centroid’ lipoprotein profiles shown
in Figure 2. A: Graphical representation of the VLDL performance diagnostic, from [25]. When applying the Particle Profiler model to a lipoprotein
profile, the uptake/production and lipolysis/production ratios in VLDL can be quantified. The information from these ratios can be summarized in a
single statistic taking the mean of these two ratios, which can be visualized as a projection on the identity line. We propose the name VLDL
performance for this projection. It integrates information about production, lipolysis and uptake rates, but can be calculated without metabolic flux
information, based on one detailed lipoprotein profile measured in one fasting blood sample. B: The analysis results. Cluster 1 (*) has a high VLDL
performance, cluster 2 (.) a lower VLDL performance, mainly due to hepatic uptake dysfunction, and cluster 3 (%) has an even lower VLDL
performance, where the further lowering is especially due to impaired extrahepatic lipolysis.
doi:10.1371/journal.pone.0038072.g003
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HDLc subgroup. Therefore, lipoprotein profile-clusters 2 and 3
taken together show a large overlap with the low HDLc subgroup,
but also identify an important new subgroup of subjects with
positive lipid response to fenofibrate treatment.
Comparison with TG subgroups. The lipoprotein-profile
based clusters also identified an additional response subgroup with
respect to the baseline triglyceride-based subgroups. The lipopro-
tein profile cluster 3 had a large overlap with the high-triglyceride
subgroup; with only 3% of the total population being unique to the
lipoprotein profile cluster and 5% of the total population being
unique to the high triglyceride subgroup (see Figure 4 for overlaps
and Table 4 for response to intervention). The main difference was
found in cluster 2, in which the lipoprotein profile clustering
included 30% of the total population that was not included in the
medium triglyceride subgroup. In these two subgroups the
response to fenofibrate of HDL and LDL parameters was similar
(see Table 5). The response of triglycerides was more pronounced
in the triglyceride-based medium risk subgroup. Therefore, we see
that lipoprotein cluster 2 identified a large additional response
subgroup, with a response to fenofibrate that was less pronounced
for triglycerides, but similar for HDL and LDL parameters.
Classification of New Samples
The described K-means classification method is applicable only
to a large sample group because of its unsupervised nature. To
allow classification of new samples into the subgroups we report,
we provide the resulting cluster centroids and standard deviations
in File S2, Supporting Tables 3a and 3b. Samples that were
measured via the same protocol and laboratory can be classified by
dividing the subclass particle concentrations (in nmol/L) by the
corresponding standard deviations (given in File S2, Supporting
Table 3b; where IDL is seen as a LDL class), and calculating the
squared Euclidean distance to all 3 centroids. Each sample is
assigned to the cluster which has the lowest resulting distance. File
S1 consists of an exel sheet that performs this calculation. It has
been shown that the laboratory method employed here has a high
degree of repeatability [26]. With this excel sheet, our clustering
can directly be applied to clinical data. Whether the clusters we
identified are indeed of clinical use, remains to be demonstrated
using studies in which hard endpoints are included.
Discussion
Earlier studies identified subgroups with different lipid response
to fenofibrate treatment, based on baseline triglycerides [8,12],
HDLc or a combination of triglycerides with HDLc or with the
LDLc/HDLc ratio [12,13]. Detailed measurements of the plasma
lipoprotein profile [16,17] are good candidates for improving the
subgroup definition for treatment response to fibrates and thus the
clinical treatment protocol, as they contain much information on
the atherogenic lipoprotein phenotype [18]. Therefore, we
compared the lipid response to fenofibrate in lipoprotein profile-
based subgroups to the response in HDLc-based and triglyceride-
based subgroups.
First, we observed that lipoprotein profile clustering yielded
subgroups with different metabolic risk profiles. In the ‘high risk’
cluster 3, subjects had higher body mass index, fasting glucose,
HOMA index, LDLc, LDL particles, triglycerides, and lower LDL
size, HDLc, and HDLp. In cluster 3 there were also significantly
more subjects with metabolic syndrome according to the Adult
Treatment Panel 3 guidelines [32] (see Table 1). As the lipid
parameters and the HOMA index indicate more severe metabolic
syndrome in the higher risk subgroup, we conclude that the
lipoprotein-based subgroups reflect differences in metabolic
health. We also see that the higher risk subgroups were more
likely to have been on lipid-lowering agents prior to the study,
which is a further indicator of metabolic disease. The modeling
results show decreasing ability to accommodate produced VLDL
particles when comparing ‘healthy’ cluster 1 to ‘high risk’ cluster 3.
In addition, the model analysis indicates that the difference
between cluster 2 and 3 is more due to extrahepatic lipolysis
dysfunction than to liver uptake dysfunction. The difference
between cluster 1 and 2 is, on the contrary, more due to liver
uptake dysfunction than to extrahepatic lipolysis dysfunction.
When Kleeman et al. [33] studied high-fat-diet induced insulin
resistance in a time-resolved and tissue specific manner in mice,
they found that the dyslipidemia and resulting insulin resistance
first affected the liver and subsequently the adipose tissue. Our
findings indicate that dyslipidemic lipoprotein metabolism dys-
function also seems to involve two stadia. The first affects liver
Figure 4. Subject overlaps between different subgroup iden-
tification methods. A: Subject overlap between the low HDLc
subgroup (dark circle) and the sum of lipoprotein profile-based cluster 2
and 3 (light circle). Figures indicate the number of subjects in each
group, in absolute numbers and as percentage of the total study
population. B: Subject overlap between the high baseline-triglyceride
subgroup (dark circle) and lipoprotein profile-based cluster 3 (light
circle). Figures indicate the number of subjects in each group, in
absolute numbers and as percentage of the total study population. C:
Subject overlap between the medium baseline-triglyceride subgroup
(dark circle) and lipoprotein profile-based cluster 2 (light circle). Figures
indicate the number of subjects in each group, in absolute numbers
and as percentage of the total study population. Lipoprotein cluster 2
clearly identifies a larger group of fibrate responders than the medium
baseline-TG group.
doi:10.1371/journal.pone.0038072.g004
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tissue). It is striking that we find these stadia using an unsupervised
clustering method, indicating that metabolic variations we observe
are among the key causes of the variance of lipoprotein profiles
within dyslipidemic heterogeneity of the GOLDN population.
From the response to fenofibrate in the different baseline
lipoprotein profile clusters, we deduce that there is less benefit
from fenofibrate treatment on lipid parameters in the subgroup
with least metabolic syndrome at baseline. The medium and high
risk subgroups both responded positively to fenofibrate, but in
different ways. The high risk subgroup experienced the largest
triglyceride lowering, LDL size increase and HDL increase while
the medium risk subgroup had the largest LDL particle benefit.
We compared the fenofibrate response in lipoprotein clusters to
the response in subgroups based on baseline HDLc or baseline
triglycerides. When comparing to the low baseline HDLc
subgroup, we saw that lipoprotein profile-clusters 2 and 3 taken
together showed a large overlap with the low HDLc subgroup, but
also identified a substantial new subgroup of fenofibrate respond-
ers. We saw that the high-risk lipoprotein cluster was very similar
to the high baseline-triglyceride subgroup, but the medium-risk
lipoprotein cluster identified a much larger response subgroup
than the medium-triglyceride subgroup. The lipoprotein profile-
based clusters, therefore, identified a large subgroup with positive
lipid response to fenofibrate treatment, additional to both previous
methodologies.
The differences in baseline characteristics and fenofibrate
response between lipoprotein clusters were biologically plausible.
Clusters 1, 2 and 3 successively had more VLDL, more and
smaller LDL and less and smaller HDL particles in their average
lipoprotein profiles. These traits are characteristic of metabolic
syndrome. It was, therefore, not surprising that we found a larger
degree of metabolic syndrome in successive clusters. The
differences between clusters also helped to explain differences in
fenofibrate response. Fibrates are PPAR-agonists [19,20] and act
to increase lipolysis of VLDL particles, to reduce cholesterol ester
and triglyceride exchange between VLDL and HDL, to increase
the removal of LDL particles, to increase HDL production and to
stimulate reverse cholesterol transport [21]. As a result of these
processes, fibrates decrease VLDL particle number, decrease LDL
particle number, increase LDL size, and increase HDL particle
number. In cluster 3, subjects exhibited abnormal values for all
these traits, and, therefore, fenofibrate intervention could correct
them all. In cluster 2, subjects had abnormal LDL and HDL traits,
but normal VLDL particle number. Fenofibrate, accordingly,
especially corrected the LDL and HDL abnormalities in these
subjects. In cluster 1, there was even the supposedly adverse affect
of a decrease in LDL size, caused by an increase in the
concentration of small LDL particles. The modeling analysis
Table 2. Percent changes after fenofibrate intervention, grouped by NMR clustering.
cluster 1 (n=350) cluster 2 (n=297) cluster 3 (n=128)
Gender Male (n=115) Female (n=235) Male (n=182) Female (n=115) Male (n=84) Female (n=44)
TG 220% 6 27% 228% 6 26% 226% 6 27% 230% 6 23% 238% 6 22%
{{ 244% 6 18%
{{
VLDLp 227% 6 45% 235% 6 45% 234% 6 34% 239% 6 38% 240% 6 23% 253% 6 20%
{
VLDL-TG 226% 6 43% 235% 6 43% 232% 6 41% 241% 6 32% 246% 6 26%
{{ 254% 6 21%
{{
HDLc 3% 6 10% 6% 6 12% 8% 6 11%
{ 7% 6 13% 10% 6 13%
{ 17% 6 12%
{{
HDLp
* 3% 6 11% 5% 6 13% 8% 6 12%
{ 6% 6 13% 11% 6 19%
{ 17% 6 21%
{{
LDLc 221% 6 12% 223% 6 14% 212% 6 14%
{ 217% 6 16%
{ 8% 6 21%
{{ 27% 6 20%
{{
LDLp
* 29% 6 14% 25% 6 18% 216% 6 14%
{ 219% 6 15%
{ 28% 6 26%
{ 217% 6 23%
{
LDL size 21.1% 6 2.8% 22.4% 6 3.0% 2.5% 6 2.5%
{ 2.4% 6 2.9%
{ 4.0% 6 3.3%
{{ 4.3% 6 3.2%
{{
{indicates significantly different with respect to cluster 1, p,0.01.
{indicates significantly different with respect to cluster 2, p,0.01.
*LDL/HDL particle number (measured by NMR).
doi:10.1371/journal.pone.0038072.t002
Table 3. Percent changes after fenofibrate intervention in low HDLc subgroup versus subjects in lipoprotein clusters 2 and 3.
cluster 2/3, not low HDL (n=137) cluster 2/3, low HDL (n=288) not cluster 2/3, low HDL (n=90)
Gender Male (n=95) Female (n=42) Male (n=171) Female (n=117) Male (n=18) Female (n=72)
TG 231% 6 25% 236% 6 24% 229% 6 27% 233% 6 22% 220% 6 32% 228% 6 23%
HDLc 7% 6 12% 6% 6 15% 10% 6 11% 11% 6 12% 6% 6 11% 11% 6 13%
HDLp
* 7% 6 13% 4% 6 14% 10% 6 16% 11% 6 16% 0% 6 13% 7% 6 12%
LDLc 211% 6 15% 220% 6 16% 22% 6 20%
{ 212% 6 18%
{ 216% 6 13%
{ 220% 6 14%
{
LDLp
* 216% 6 15% 219% 6 16% 212% 6 21% 219% 6 18% 211% 6 15% 210% 6 15%
{{
LDL size 2.6% 6 2.9% 1.2% 6 2.7% 3.2% 6 2.9% 3.6% 6 3.0%
{ 0.7% 6 2.4%
{{ 20.5% 6 2.6%
{{
{indicates significantly different with respect to cluster 2/3 and not low HDL subgroup, p,0.01.
{indicates significantly different with respect to cluster 2/3 and low HDL subgroup, p,0.01.
*LDL/HDL particle number (measured by NMR).
doi:10.1371/journal.pone.0038072.t003
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progressively more related to extrahepatic lipolysis dysfunction
compared to liver uptake dysfunction. The lipid response to
fenofibrate indicates that fenofibrate can play a role in correcting
both these dysfunctions. Hence, the differences in response
between clusters can be understood mechanistically.
The current clustering is based on subjects in the GOLDN
study, a genetically homogeneous, white population. Whether the
same clusters are valid for other populations remains to be seen,
but this approach is widely applicable. The fact that clusters reflect
known lipoprotein abnormalities and the metabolic syndrome is
encouraging. It would be interesting to perform this type of
clustering with data from other fenofibrate trials [11,15].
The additional responder subgroup is mainly identified in
lipoprotein cluster 2, which we expect to show clinical benefit.
Lipoprotein cluster 2 had a lower triglyceride response to
fenofibrate than the medium baseline triglyceride subgroup. This
smaller triglyceride lowering may be an obstacle to clinical
benefit, because an analysis of the Veterans Affairs HDL
Intervention Trial showed an increase of coronary heart disease
events per 50-mg/dl increase of triglycerides at baseline [14]. On
the other hand, the response of LDL particles in lipoprotein
cluster 2 is at least as good as in the medium baseline-triglyceride
subgroup, which may well indicate decreased risk [34], and also
the decrease in HDLc [35] and increase in LDL size [36] in this
cluster do indicate beneficial effects from fenofibrate. Whether
this is sufficient to translate into fewer cardiovascular events
remains to be demonstrated. Trials such as FIELD [11] and
ACCORD [15,37] may provide the data to test the clinical
benefit.
We compared our lipoprotein profile-based subgroups to
baseline triglyceride-based and HDLc-based subgroups. Other
reports also used a combination of the high triglyceride cutoff with
a HDLc cutoff or a LDLc versus HDLc ratio cutoff [12,13]. Such
a combination of cutoffs would take into account more risk factors,
similar to a complete lipoprotein-profile approach. Yet, we did not
include the comparison with these subgroups because our high-risk
subgroup corresponded very well to the high triglyceride
subgroup. Adding additional cutoffs to this high risk subgroup
would narrow the subgroup, and make it less comparable to our
high-risk subgroup. However, using additional cutoffs could be
useful for defining an even higher-risk subgroup than that based
on lipoprotein clustering alone. The primary use of lipoprotein
clustering is to identify two responder subgroups, containing a
larger number of responder subjects than identified using other
subgrouping methods.
Although the lipoprotein profile-based groups do show differ-
ences in HOMA levels, the lipoprotein profile itself does not
include information on the possible diabetic or insulin resistant
states of subjects. This information is relevant because subgroup
analysis of the VA-HIT study has demonstrated that lowering
triglycerides with the fibrate gemfibrozil more effectively reduces
cardiovascular events in diabetic subjects than in non-diabetic
subjects [14]. Therefore, any subgrouping for cardiovascular risk
Table 4. Percent changes after fenofibrate intervention in high TG subgroup versus lipoprotein cluster 3.
cluster 3, high TG (n=104) cluster 3, not high TG (n=24) not cluster 3, high TG (n=35)
Gender Male (n=67) Female (n=37) Male (n=17) Female (n=7) Male (n=14) Female (n=21)
TG 241% 6 20% 245% 6 18% 227% 6 26% 241% 6 18% 253% 6 18%
{ 244% 6 17%
HDLc 10% 6 13% 18% 6 13% 11% 6 13% 13% 6 10% 9% 6 15% 7% 6 12%
{
HDLp
* 10% 6 18% 19% 6 21% 14% 6 22% 7% 6 18% 6% 6 12% 6% 6 15%
LDLc 11% 6 21% 26% 6 17% 25% 6 17%
{ 212% 6 30% 21% 6 16% 217% 6 12%
LDLp
* 25% 6 28% 216% 6 21% 221% 6 10% 224% 6 33% 215% 6 21% 215% 6 16%
LDL size 3.9% 6 3.4% 4.0% 6 3.1% 4.7% 6 3.2% 5.9% 6 3.6% 3.8% 6 3.0% 1.4% 6 4.0%
{
{indicates significantly different with respect to cluster 3 and high TG subgroup, p,0.01.
{indicates significantly different with respect to cluster 3 and not high TG subgroup, p,0.01.
*LDL/HDL particle number (measured by NMR).
doi:10.1371/journal.pone.0038072.t004
Table 5. Percent changes after fenofibrate intervention in medium TG subgroup versus lipoprotein cluster 2.
cluster 2, medium TG (n=64) cluster 2, not medium TG (n=233) not cluster 2, medium TG (n=49)
Gender Male (n=35) Female (n=29) Male (n=147) Female (n=86) Male (n=21) Female (n=28)
TG 237% 6 22% 240% 6 19% 223% 6 27%
{ 227% 6 24%
{ 229% 6 25% 246% 6 17%
{
HDLc 7% 6 9% 4% 6 10% 9% 6 11% 8% 6 13% 10% 6 12% 12% 6 13%
{
HDLp
* 11% 6 14% 5% 6 12% 8% 6 12% 6% 6 13% 11% 6 22% 3% 6 17%
LDLc 28% 6 15% 216% 6 17% 213% 6 14% 217% 6 16% 26% 6 17% 219% 6 18%
LDLp
* 211% 6 17% 218% 6 17% 217% 6 14% 220% 6 14% 216% 6 13% 213% 6 24%
LDL size 2.9% 6 2.7% 3.0% 6 2.8% 2.4% 6 2.5% 2.3% 6 2.9% 3.8% 6 3.8% 1.0% 6 4.2%
{indicates significantly different with respect to cluster 2 and medium TG subgroup, p,0.01.
{indicates significantly different with respect to cluster 2 and not medium TG subgroup, p,0.01.
*LDL/HDL particle number (measured by NMR).
doi:10.1371/journal.pone.0038072.t005
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diabetes or insulin resistance information. Recent trials have only
used type II diabetic patients [11,37], and so provide an excellent
opportunity for lipoprotein profile-based analysis.
Using this new lipoprotein profile clustering methodology, we
have identified two distinct subgroups of subjects with positive lipid
response to fenofibrate therapy. Modeling analysis suggests that
the difference between the subgroups with low and medium
dyslipidemia is influenced mainly by hepatic uptake dysfunction,
while the difference between subgroups with medium and high
dyslipidemia is influenced mainly by extrahepatic lipolysis
disfunction. This is a new insight into the metabolic disturbances
that underlie the variation in lipoprotein metabolism at the
population level. The total number of identified responder subjects
is larger than those based on previously reported baseline HDLc
and triglyceride cutoffs. Our findings are key to the post-hoc
analysis of large clinical trials such as FIELD [11] and ACCORD
[37] because a larger subgroup with positive response translates
into greater statistical power to show treatment benefit in that
subgroup. Also, by employing lipoprotein profile diagnostics, more
patients can benefit from fenofibrate treatment.
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